Research Article: Clinical significance of high monocyte counts for the continuous treatment with nintedanib
Abstract:
Nintedanib is now widely used to treat interstitial lung disease (ILD). Adverse events, which occur in not a few patients, make it difficult to continue nintedanib treatment, but the risk factors for adverse events are not well understood.
Introduction:
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause characterized by chronic and progressive fibrosis. IPF has a histopathologic UIP pattern and is rapidly progressive disease with a poor prognosis. The pathogenesis of IPF is not fully understood; however, recent reports have demonstrated the efficacy of the antifibrotic agents nintedanib and pirfenidone [1, 2]. Similarly, systemic sclerosis (SSc) is known to cause lung fibrosis. The clinical course of patients with sclerosis varies, and…
Read more